Disclosures for "Initial Validity and Clinical Utility of the Moticon Insole System for Assessing Gait in Parkinson’s Disease"
-
Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from NIH.
-
The institution of Dr. Kwei has received research support from New York Community Trust.
-
Dr. Purcell has nothing to disclose.
-
The institution of Miss Timm has received research support from National Fragile X Foundation.
-
Author has nothing to disclose
-
Mr. Koyani has received personal compensation for serving as an employee of Regeneron. Mr. Koyani has stock in Regeneron.
-
Dr. Robertson has received personal compensation for serving as an employee of Regeneron Pharmaceuticals Inc. Dr. Robertson has stock in Regeneron Pharmaceuticals Inc.
-
Dr. Wipperman has received personal compensation for serving as an employee of Regeneron Pharmaceuticals. Dr. Wipperman has stock in Regeneron Pharmaceuticals.
-
Dr. Levy has received personal compensation for serving as an employee of Regeneron Pharmaceuticals . Dr. Levy has stock in Regeneron Pharmaceuticals .
-
Dr. O'Keefe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Department of Defense.